PT Kalbe Farma TbkFRA:LCLA -29.79%77 Operating Margin % is 13.62% as of Mar. 2026, which is 8% below its 10-year median of 14.83. GuruFocus rates FRA:LCLA with a GF Score™ of 77/100 and a GF Value™ of €0.07 (Significantly Undervalued). The stock has 2 warning signs investors should review. Among 955 Drug Manufacturers companies, PT Kalbe Farma Tbk ranks better than 62.83% on this metric.
PT Kalbe Farma Tbk operating margin has been in a 5-year decline. The average rate of decline per year is -4.7%.
The historical rank and industry rank for PT Kalbe Farma Tbk's Operating Margin % or its related term are showing as below:
FRA:LCLA'
s Operating Margin % Range Over the Past 10 Years
Min: 11.91 Med: 14.83 Max: 16.08
Current: 12.39
FRA:LCLA's Operating Margin % is ranked better than 62.83% of 955
companies
in the Drug Manufacturers industry
Industry Median: 7.45
vs FRA:LCLA: 12.39
PT Kalbe Farma Tbk's 5-Year Average Operating Margin % Growth Rate was -4.70% per year.
Just like Gross Margin %, it is important to see a company maintains its operating margin over time. Among the same industry, a company with higher operating margin is more efficient in its operation. It is also more stable during industry slowdown or recessions. Peter Lynch prefers those with higher margins than those with lower margins.
Be Aware
Operating Margin % can be manipulated by adjusting the rate of depreciation, depletion and amortization (DDA).
If a company is facing competition, its Operating Margin % may decline. Often the Operating Margin % declines well before the company's Revenue or even profit decline. Therefore, Operating Margin % is a very important indicator of whether the company is facing problems.
For instance, by 2012, Nokia (NOK)'s problems were well known and its stock had lost more than 90% of its market value since 2007. But Nokias Operating Margin % had already been in decline since 2002, although its Earnings per Share (Diluted) were still rising. Investors who paid attention to Operating Margin % would have avoided this huge loss. The same can be said for Research-in-Motion (RIMM).
Therefore, Operating Margin % is a very important screening filter for GuruFocus. GuruFocus's Buffett-Munger screener requires that the profit margin is either consistent or expanding. The Model Portfolio of the Buffett-Munger screener has outperformed the market every year since inception in 2009.
PT Kalbe Farma Tbk Operating Margin % Related Terms
PT Kalbe Farma Tbk Operating Margin % Historical Data
* Premium members only.
The historical data trend for PT Kalbe Farma Tbk's Operating Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
FRA:LCLA vs LLY, JNJ, ABBV: Operating Margin % Comparison
For the Drug Manufacturers - General subindustry, PT Kalbe Farma Tbk's Operating Margin %, along with its competitors' market caps and Operating Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
PT Kalbe Farma Tbk Operating Margin % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, PT Kalbe Farma Tbk's Operating Margin % distribution charts can be found below:
* The bar in red indicates where PT Kalbe Farma Tbk's Operating Margin % falls into.
Operating Margin % - also known as operating income margin, operating profit margin and return on sales (ROS) - is the ratio of Operating Income divided by net sales or Revenue, usually presented in percent.
PT Kalbe Farma Tbk's Operating Margin % for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
PT Kalbe Farma Tbk (FRA:LCLA) has a Operating Margin % of 13.62% as of Mar. 2026. Operating margin is the ratio of total operating income to net sales. View historical data on PT Kalbe Farma Tbk and its competitors. This is near median its historical median of 14.83. Over the past decade, PT Kalbe Farma Tbk's Operating Margin % has ranged from 11.91 to 16.08. According to the industry distribution chart, PT Kalbe Farma Tbk ranks #355 out of 955 companies in the Drug Manufacturers industry, placing it in the top 37.2%.
Is PT Kalbe Farma Tbk's Operating Margin % too high?
PT Kalbe Farma Tbk's current Operating Margin % of 13.62% is near median its 10-year median of 14.83. Over the past 10 years, this metric has ranged from a low of 11.91 to a high of 16.08. The Drug Manufacturers industry median Operating Margin % is 7.45. PT Kalbe Farma Tbk's value of 13.62% is 82.8% above this industry median. Based on the distribution chart, PT Kalbe Farma Tbk ranks #355 out of 955 companies in the Drug Manufacturers industry, which is above the industry midpoint. Overall, PT Kalbe Farma Tbk has a GF Score™ of 77/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does PT Kalbe Farma Tbk's Operating Margin % compare to LLY and JNJ?
According to the Drug Manufacturers industry distribution chart, PT Kalbe Farma Tbk ranks #355 out of 955 companies for Operating Margin %. This puts PT Kalbe Farma Tbk in the upper half of its industry. The industry median Operating Margin % is 7.45. PT Kalbe Farma Tbk's value of 13.62% is 82.8% above this benchmark. Historically, PT Kalbe Farma Tbk's own Operating Margin % has ranged from 11.91 to 16.08 over the past decade. While the company's 10-year median is 14.83 vs. the industry median of 7.45, PT Kalbe Farma Tbk has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Operating Margin % for a Drug Manufacturers company?
The median Operating Margin % among Drug Manufacturers companies is 7.45, based on 955 companies in the industry. Companies in the top quartile (top 25%) have a Operating Margin % significantly above this median, while those in the bottom quartile fall well below. However, Operating Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. PT Kalbe Farma Tbk's current Operating Margin % of 13.62% is 82.8% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Operating Margin % mean?
A high Operating Margin % can signal that a stock is expensive relative to its fundamentals. Operating margin is the ratio of total operating income to net sales. View historical data on PT Kalbe Farma Tbk and its competitors. For the Drug Manufacturers industry, the median Operating Margin % is 7.45 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. PT Kalbe Farma Tbk's current Operating Margin % is 13.62%, which is near median its own 10-year median of 14.83. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is PT Kalbe Farma Tbk stock overvalued right now?
Based on GuruFocus' analysis, PT Kalbe Farma Tbk (FRA:LCLA) is currently considered Significantly Undervalued. The stock's GF Value™ is €0.07, compared to a current price of €0.03 — trading 52.9% below its estimated fair value. The current Operating Margin % is 13.62%, which is near median its 10-year median of 14.83 and 82.8% above the Drug Manufacturers industry median of 7.45. PT Kalbe Farma Tbk's overall GF Score™ is 77/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Operating Margin % calculated?
Operating Margin % is calculated from a company's financial statements. For PT Kalbe Farma Tbk (FRA:LCLA), the current Operating Margin % is 13.62% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is PT Kalbe Farma Tbk (FRA:LCLA) Overvalued in 2026?
Based on GuruFocus' analysis, PT Kalbe Farma Tbk stock appears to be undervalued.
The current stock price of €0.03 is trading 52.9% below its estimated GF Value™ of €0.07.
GuruFocus considers PT Kalbe Farma Tbk to be Significantly Undervalued.
Key valuation signals for FRA:LCLA:
Operating Margin %: 13.62% (near median its 10-year median of 14.83)
GF Value™: €0.07 vs. price of €0.03 (52.9% below fair value)
Industry Position: 82.8% above the Drug Manufacturers median (#355 of 955)
No single metric tells the full story. See the FRA:LCLA stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
PT Kalbe Farma Tbk is engaged in the development, manufacturing, and trading of pharmaceutical products, including human medicines and consumer health products. The company operates four segments: prescription pharmaceuticals, consumer health, Nutritionals, and distribution and logistics. The majority of the company's revenue is derived from the distribution and logistics segments. Its Product and Services are Prescription /Ethicals, Consumer Health, Nutritionals, Distribution & Logistics, Health Services, Medical Devices, and Others.
77GF Score
Get the complete analysis for FRA:LCLA
Operating Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:LCLA has been successfully added to your 
